Bujold, Emmanuel MD, MSc, FRCSC - Regular researcher


Full professor - Université Laval

(1) Reproduction, mother and child health axis, Centre Hospitalier Universitaire de Québec — Université Laval

(2) Obstetrics, gynaecology and reproduction axis, Faculty of Medicine

Research interest

  • Research on the origin and prevention of pre-eclampsia
  • Research on the placental origine of preterm birth
  • Research on VBAC and uterine rupture 

See details on research interest in the "complementary information" tab 

Expertise

Pregnancy Preeclampsia Prediction and prevention Prématurité

Centre de recherche du CHU de Québec (CHUL)

2705 boul. Laurier
Québec (QC) Canada
G1V 4G2
(418) 525-4444 extension : 47530
Fax : (418) 577-4675
emmanuel.bujold@crchudequebec.ulaval.ca

Research chair

Jeanne-et-Jean-Louise-Lévesque research chair on perinatality

Others links

https://www.researchgate.net/profile/Emmanuel_Bujold

Postdoctoral fellowship: Feto-maternal medicine specialty-Maternelle, Wayne State University (Detroit, MI, USA)

PhD: Médecine, Université de Montréal (Montréal, QC, Canada)

MSc: Épidémiologie, Université Laval (Québec, QC, Canada)

Obstetric-Gynecology specialty



1 Latest projects

  • Récepteur P2Y14, inflammation et pré-éclampsie

Research on the origin and prevention of pre-eclampsia

In 2005, Dr Bujold has demonstrated the uterine origin of sVEGFR1- in pre-eclampsia and has provided a direct proof of the utero-placental origin of pre-eclampasia (Bujold E et al. J Matern Fetal Neonatal Med 2005;18:9). Since then, his work has enabled a better understanding of previous controversial work stating the role of uterine Doppler in the prediction of pre-eclampsia (Lefebvre et al. Ultrasound Obstet Gynecol 2012) and more importantly, he has found a solution to the important controversy associated to contradictory results of more than 50 randomised trials that have evaluated the role of aspirin in the prevention of pre-eclampsia. First of all, is as highlighted the necessity of starting aspirin in the first trimester (Bujold E et al. Obstet Gynecol 2010, cité >400 fois) and then he demonstrated that its benefit was associated with severe and pre-term cases of the disease, while non-severe cases were not affected (Roberge et al. Fetat Diagn Therapy 2012 & Am J Perinatol 2012). He is now a guest speakers invited many times a year to international meetings (14 countries). After having demonstrated it was possible to detect early pre-eclampsia using 3D echo (SMFM 2014 award), he received $998K from CIHR (2014-2019) to confirm these major results.

Research on the placental origin of pre-term birth

Dr Bujold aimed a major part of his fellowship (2001-2004) to the search for intra-amniotic and plancental markers for pre-term labor and premature and pre-term rupture of membranes. With Dr Yeon Mee Kim, pediatric pathologist, he has first confirmed the early origin and multiple etiology of pre-term labor and delivery (Kim YM, Bujold E, et al. Am J Obstet Gynecol 2003;189:1063 ; and Kim et al. Am J Obstet Gynecol 2002;187:1137). Rewarded for this work (SMFM 2003), he then demonstrated the benefit of aspirin for the prevention of prematurity (Bujold E et al. J Matern Fetal Neonatal Med. 2011;24:966). He is currently evaluation the prediction of prematurity at the 2st trimester.

Research on VBAC and uterine rupture

Since 2002, Dr Bujold published more than 30 articles associated to the risk factors of uterine rupture and to vaginal birth after caesarean (VBAC) such as 1) the risk of one plane closing, 2)the inter-delivery interval, 3)the morbidity of uterine rupture, 4) the importance of cervical maturity and 5) the role of inferior segment measuring in the prediction of uterine rupture. IN 2015, he received with Nils Chaillet, PhD, $2.9M from CIHR to evaluate these discoveries within a pan-Quebec ECR (PRISMA).